Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VERA
VERA THERAPEUTICS, INC.
NASDAQ
$34.19
▼ DOWN 1.18% (-0.41)

KEY STATISTICS

Market Cap$2.45 B
52w High$56.05
52w Low$21.64
Dividend Yield—
Frequency—
P/E-5.83
Volume1.26M
Shares Out.71.78M

COMPANY

LEADERSHIP

Marshall Fordyce
CHIEF EXECUTIVE
Marshall Fordyce

COMPENSATION 2026

Salary$660,000
Stock Awards$2,356,285
Incentive Plan Pay$554,400
All Other Comp.$0
Total$6,986,410

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 14, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
361

PRICE TARGET

Target High$125.00
Target Low$43.00
Target Median$87.00
Target Consensus$86.75

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$4.28M
NOV
4
WED

PRICE

$34.19 ▼ DOWN 1.18% (−$0.41)
$33.60$33.90$34.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM34.19

About Vera Therapeutics, Inc.

https://veratx.com ↗

Vera Therapeutics, Inc. is a clinical-stage biotech company developing immunological treatments like atacicept for IgA nephropathy and MAU868 for BK viremia, headquartered in Brisbane, CA.

INDUSTRY

Biotechnology

A PRODUCT VERA THERAPEUTICS, INC. IS KNOWN FOR

Atacicept
Atacicept

Atacicept, Vera Therapeutics' lead candidate for IgAN, is a first-in-class fusion protein in late-stage development that blocks BAFF and APRIL, with FDA Breakthrough Therapy Designation, and is administered via subcutaneous injection.

COMPETITORS

COMPETITOR
ARWR COMPARE
NVS COMPARE
TVTX COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
131
LISTED HERE
24
RANKED BY POSITION SIZE
XBI
0.82% · 2.8M
VTI
0.00% · 1.9M
XSU.TO
0.07% · 1.6M
SCHA
0.05% · 314.3K
FESM
0.10% · 194.4K
DFMC
0.08% · 173.5K
XSXD.SG
0.04% · 104.5K
LABU
0.56% · 102.4K
TMSL
0.11% · 92.1K
SBIO
1.25% · 88.5K
RSSL
0.07% · 30.5K
OP
OPTZ
0.40% · 18.1K
BBSC
0.07% · 15.2K
PRFZ
0.01% · 12.0K
BBC
0.60% · 9.2K
TILT
0.01% · 5.2K
ACSG
0.30% · 4.5K
URTY
0.03% · 2.6K
STXK
0.09% · 2.2K
BKSE
0.07% · 1.9K
VETS
0.18% · 1.6K
RFLR
0.06% · 1.6K
USFMDN.MX
0.00% · 217
RESM
0.06% · 115

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.08%
HOLDERS
304
TOP 12 OF 304 · RANKED BY POSITION SIZE
Avoro Capital Advisors LLC
6.2M sh · $180.46M
Blackrock, Inc.
5.7M sh · $246.64M
Price T Rowe Associates Inc /Md/
5.5M sh · $276.6M
State Street Corp
4.1M sh · $178.02M
Deep Track Capital, LP
4.1M sh · $165.19M
Deerfield Management Company, L.P. (Series C)
4.1M sh · $205.58M
Kynam Capital Management, LP
4.0M sh · $117.05M
Vanguard Group Inc
3.6M sh · $180.81M
Blackrock Inc.
3.3M sh · $120.76M
Eversept Partners, LP
3.1M sh · $155.58M
Abingworth Llp
3.0M sh · $57.28M
Fmr LLC
2.9M sh · $146.14M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Fordyce Marshall
Sale · 10.5K shares
2026-07-07
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Fordyce Marshall
Sale · 1.0K shares
2026-07-07
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Fordyce Marshall
Sale · 2.2K shares
2026-07-07
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Fordyce Marshall
Sale · 32.5K shares
2026-07-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 2
NEUTRAL 1
OVERWEIGHT 1
9 GRADES IN THE LAST 12 MONTHS
Wedbush NEUTRAL HC Wainwright & Co. BUY Guggenheim BUY TD Cowen BUY B of A Securities BUY Evercore ISI Group OUTPERFORM Wolfe Research OUTPERFORM Goldman Sachs BUY

SECTORS PEERS

PEERPRICE
ABCL$11.35COMPARE
QURE$48.72COMPARE
IMNM$27.57COMPARE
VRDN$23.08COMPARE
CLDX$39.12COMPARE
PHVS$35.32COMPARE
BHVN$15.41COMPARE
NUVB$6.66COMPARE